Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company Drug

Jiangxi Jemincare Secures First Generic Approval for GSK’s Requip in China

Fineline Cube Aug 28, 2024

Jiangxi Jemincare Group, based in China, has received marketing approval from the National Medical Products...

Company

AstraZeneca to Invest $135 Million in Swedish Biomanufacturing Facility Expansion

Fineline Cube Aug 28, 2024

AstraZeneca (NASDAQ: AZN, LON: AZN) , the UK-based biopharmaceutical leader, has announced a plan to...

Company Deals

Peijia Medical Secures Exclusive Rights to NowYon’s YonFlow Device in Greater China

Fineline Cube Aug 28, 2024

Peijia Medical Ltd (HKG: 9996) has entered into a licensing agreement with NowYon Medical, securing...

Company Drug

Sanofi Halts Flu Vaccine Distribution in China Amid Potency Concerns

Fineline Cube Aug 28, 2024

Sanofi (NASDAQ: SNY), the French pharmaceutical giant, has reportedly suspended the distribution and sale of...

Company Deals

Frontier Biotechnologies to Sell 70% of API Unit to Duo Rui Pharma for RMB 10 Million

Fineline Cube Aug 28, 2024

Nanjing-based Frontier Biotechnologies Inc. is poised to divest a 70% stake in its peptide active...

Company

Johnson & Johnson China’s Cardiovascular and Professional Solutions Division Head, Kevin Chen, Resigns for New Opportunities

Fineline Cube Aug 28, 2024

Johnson & Johnson (J&J, NYSE: JNJ), a leading US multinational conglomerate, has announced the resignation...

Company

Everest Medicines Reports 158% Revenue Growth in 2024 H1, Driven by Pharmaceutical Sales and Operational Efficiency

Fineline Cube Aug 28, 2024

Everest Medicines, a China-based biopharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 1952),...

Company Drug

JW Therapeutics’ CAR-T Therapy Carteyva Secures NMPA Approval for Mantle Cell Lymphoma Indication

Fineline Cube Aug 28, 2024

JW Therapeutics, a biopharmaceutical company based in China and listed on the Hong Kong Stock...

Company Drug

Shanghai-Based ANEXT Commences Clinical Trials for Exosome Product ANEXT FIT CELL in Respiratory Conditions

Fineline Cube Aug 28, 2024

ANEXT, a Shanghai-based exosome specialist, has launched two clinical studies for their product ANEXT FIT...

Company

Shanghai Fosun Pharmaceutical Reports 5.31% YOY Revenue Growth and Strong R&D Investment in 2024H1 Report

Fineline Cube Aug 28, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd, listed on the Shanghai Stock Exchange (SHA: 600196) and...

Company Deals

Shanghai BDgene Partners with SPH RD to Develop Hemophilia Treatments Using BDlendi Insulator Technology

Fineline Cube Aug 28, 2024

Shanghai BDgene Technology Co., Ltd, a leading gene therapy specialist based in China, has entered...

Company Drug

Legend Biotech’s Carvykti Receives NMPA Approval for Relapsed/Refractory Multiple Myeloma After Multi-Center Phase II Study

Fineline Cube Aug 28, 2024

Legend Biotech Corporation (NASDAQ: LEGN) has secured a significant milestone with the announcement of marketing...

Company Drug

Jiangsu Hengrui’s Vunakizumab Receives NMPA Approval as First Homegrown Autoimmune IL-17A Drug

Fineline Cube Aug 28, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd, a Chinese pharmaceutical company listed on the Shanghai Stock Exchange...

Company

Luye Pharma’s Subsidiary Boan Bio Reports 2024H1 Revenue Growth and First Full Year of Profitability

Fineline Cube Aug 28, 2024

Luye Pharma Group, a Chinese pharmaceutical company listed in Hong Kong (HKG: 2186), has announced...

Company Drug

Hinova Pharmaceuticals’ HP515 Receives NMPA Approval for NASH Clinical Study

Fineline Cube Aug 28, 2024

Hinova Pharmaceuticals Inc., a biotech firm headquartered in Chengdu and listed on the Shanghai Stock...

Company

Walvax Biotechnology Reports 2024H1 Revenue Dip Amid Intense Vaccine Market Competition

Fineline Cube Aug 28, 2024

Walvax Biotechnology Co., Ltd, a Chinese vaccine manufacturer listed on the Shenzhen Stock Exchange (SHE:...

Company Drug

Bio-Thera Solutions’ BAT8006 Receives NMPA Approval for Clinical Trial in Recurrent Ovarian Cancer Maintenance Therapy

Fineline Cube Aug 28, 2024

Bio-Thera Solutions, a biopharmaceutical company based in Guangzhou and listed on the Shanghai Stock Exchange...

Company Drug

Chongqing Genrix Biopharmaceutical Receives NMPA Approval for Xeligekimab, First Domestic Anti-IL-17 Antibody

Fineline Cube Aug 27, 2024

Chongqing Genrix Biopharmaceutical Co., Ltd, a Chinese biopharmaceutical company, has received marketing approval from China’s...

Legal / IP

Takeda’s Entyvio Receives Historic Patent Term Adjustment in China, a First for the Country

Fineline Cube Aug 27, 2024

On August 16, a significant milestone was reached as the China National Intellectual Property Administration...

Policy / Regulatory

NHSA Updates NRDL Review, Adds Three Domestic Western Medicines

Fineline Cube Aug 27, 2024

The National Healthcare Security Administration (NHSA) has issued a notification regarding the review and correction...

Posts pagination

1 … 360 361 362 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.